Rocket Pharmaceuticals, Inc. (RCKT) financial statements (2021 and earlier)

Company profile

Business Address 350 FIFTH AVENUE
NEW YORK, NY 10118
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:483229250276304241258
Cash and cash equivalents297821631911858965
Short-term investments1861468785119151193
Other undisclosed cash, cash equivalents, and short-term investments(0)0(0)0(0)00
Other undisclosed current assets5564456
Total current assets:487233255280308246264
Noncurrent Assets
Finance lease, right-of-use asset51534948   
Operating lease, right-of-use asset1111222
Property, plant and equipment19161411291910
Intangible assets, net (including goodwill)31313131313131
Goodwill31313131313131
Deposits noncurrent assets0000000
Restricted cash and investments2222222
Other undisclosed noncurrent assets    0  
Total noncurrent assets:1031029893645445
TOTAL ASSETS:591335353373372300309
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:25251819172114
Accounts payable1643441
Accrued liabilities2112111
Employee-related liabilities5321321
Interest and dividends payable1111101
Other undisclosed accounts payable and accrued liabilities1614101381410
Debt7622111
Other undisclosed current liabilities111    
Total current liabilities:33322121182215
Noncurrent Liabilities
Long-term debt and lease obligation55626666464645
Long-term debt, excluding current maturities35424646454443
Finance lease, liability19191919   
Operating lease, liability0111122
Liabilities, other than long-term debt0000000
Other liabilities0000000
Total noncurrent liabilities:55626666474645
Total liabilities:87948787656860
Stockholders' equity
Stockholders' equity attributable to parent504242267286307232249
Common stock1111111
Treasury stock, value (0) (0)(0)(0)(0)
Additional paid in capital826503499494490395392
Accumulated other comprehensive income (loss)(0)00(0)000
Accumulated deficit(323)(262)(233)(208)(183)(163)(144)
Total stockholders' equity:504242267286307232249
TOTAL LIABILITIES AND EQUITY:591335353373372300309

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Operating expenses(59)(27)(24)(24)(20)(19)(18)
Operating loss:(59)(27)(24)(24)(20)(19)(18)
Interest and debt expense(2)(2)(2)(2)(1)(1)(2)
Net loss:(61)(29)(25)(26)(21)(21)(20)
Other undisclosed net income (loss) attributable to parent(0)001111
Net loss available to common stockholders, diluted:(61)(29)(25)(25)(20)(19)(19)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(61)(29)(25)(26)(21)(21)(20)
Comprehensive loss:(61)(29)(25)(26)(21)(21)(20)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)011111
Comprehensive loss, net of tax, attributable to parent:(61)(29)(25)(25)(20)(19)(18)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: